EE05003B1 - Dihdro-1,3,5-triasiinamino derivaadid ja nende kasutamine ravis - Google Patents

Dihdro-1,3,5-triasiinamino derivaadid ja nende kasutamine ravis

Info

Publication number
EE05003B1
EE05003B1 EEP200200414A EEP200200414A EE05003B1 EE 05003 B1 EE05003 B1 EE 05003B1 EE P200200414 A EEP200200414 A EE P200200414A EE P200200414 A EEP200200414 A EE P200200414A EE 05003 B1 EE05003 B1 EE 05003B1
Authority
EE
Estonia
Prior art keywords
triazinamino
therapy
derivatives
dih dro
dih
Prior art date
Application number
EEP200200414A
Other languages
English (en)
Estonian (et)
Inventor
Moinet G�Rard
Cravo Daniel
Doare Liliane
Kergoat Micheline
Mesangeau Didier
Original Assignee
Lipha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8846333&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE05003(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lipha filed Critical Lipha
Publication of EE200200414A publication Critical patent/EE200200414A/xx
Publication of EE05003B1 publication Critical patent/EE05003B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/10—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/72—Heterocyclic compounds containing 1,3,5-triazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP200200414A 2000-01-26 2001-01-25 Dihdro-1,3,5-triasiinamino derivaadid ja nende kasutamine ravis EE05003B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0000996A FR2804113B1 (fr) 2000-01-26 2000-01-26 Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique
PCT/FR2001/000241 WO2001055122A1 (fr) 2000-01-26 2001-01-25 Derives amines de dihydro-1,3,5-triazine et leurs applications en therapeutique

Publications (2)

Publication Number Publication Date
EE200200414A EE200200414A (et) 2003-10-15
EE05003B1 true EE05003B1 (et) 2008-04-15

Family

ID=8846333

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200414A EE05003B1 (et) 2000-01-26 2001-01-25 Dihdro-1,3,5-triasiinamino derivaadid ja nende kasutamine ravis

Country Status (36)

Country Link
US (4) US7034021B2 (cs)
EP (1) EP1250328B2 (cs)
JP (1) JP4926357B2 (cs)
KR (1) KR100722438B1 (cs)
CN (1) CN1195743C (cs)
AP (1) AP2002002578A0 (cs)
AR (1) AR027293A1 (cs)
AT (1) ATE332294T1 (cs)
AU (1) AU782307B2 (cs)
BG (1) BG106933A (cs)
BR (1) BRPI0107815B8 (cs)
CA (1) CA2397636C (cs)
CY (1) CY1105344T1 (cs)
CZ (1) CZ303445B6 (cs)
DE (1) DE60121294T3 (cs)
DK (1) DK1250328T4 (cs)
EA (1) EA005378B1 (cs)
EE (1) EE05003B1 (cs)
ES (1) ES2267715T5 (cs)
FR (1) FR2804113B1 (cs)
HR (1) HRP20020625A2 (cs)
HU (1) HU230790B1 (cs)
IL (1) IL150530A0 (cs)
IS (1) IS6467A (cs)
MA (1) MA25650A1 (cs)
MX (1) MXPA02007232A (cs)
NO (1) NO20023532L (cs)
OA (1) OA12165A (cs)
PL (1) PL205345B1 (cs)
PT (1) PT1250328E (cs)
SI (1) SI1250328T2 (cs)
SK (1) SK287647B6 (cs)
TN (1) TNSN01012A1 (cs)
WO (1) WO2001055122A1 (cs)
YU (1) YU55602A (cs)
ZA (1) ZA200205314B (cs)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804113B1 (fr) * 2000-01-26 2004-06-18 Lipha Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique
US7622469B2 (en) 2002-12-17 2009-11-24 Hamari Chemicals, Ltd. 2,4-diamino-1,3,5-triazine derivatives
FR2853650B1 (fr) * 2003-04-10 2006-07-07 Merck Sante Sas Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance
ATE489370T1 (de) * 2005-06-14 2010-12-15 Schering Corp Herstellung und verwendung von verbindungen als aspartylproteasehemmer
FR2896160B1 (fr) * 2006-01-13 2008-04-25 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agonistes du ppar alpha.
FR2896157B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
FR2896158B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'inhibiteurs de la hmg-coa reductase.
FR2896159B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.
FR2896161B1 (fr) * 2006-01-13 2008-04-04 Merck Sante Soc Par Actions Si Utilisation de derives de triazines pour fabriquer un medicament ayant un effet cicatrisant ou angiogenique.
DE102007054416A1 (de) * 2007-11-13 2009-05-14 Studiengesellschaft Kohle Mbh Verfahren zur Herstellung von 3,6-Dihydro-1,3,5- Triazin-Derivaten für die Behandlungen von Erkrankungen, die mit dem Insulinresistenz-Syndrom assoziiert sind
DE102008007314A1 (de) 2008-02-02 2009-08-06 Merck Patent Gmbh Verfahren zur Herstellung von 3,6-Dihydro-1,3,5-triazinderivaten
ATE536347T1 (de) 2008-05-20 2011-12-15 Merck Sharp & Dohme Effiziente herstellung heterologer proteine unter verwendung von mannosyltransferaseinhibitoren
US20110124860A1 (en) * 2008-05-23 2011-05-26 Aubourg Stephanie Process for the synthesis of 3,6-dihydro-1,3,5-triazine derivatives
WO2010024225A1 (ja) * 2008-08-25 2010-03-04 浜理薬品工業株式会社 新規ジヒドロトリアジン誘導体
ES2530223T3 (es) 2008-12-12 2015-02-27 Poxel S.A.S. Combinación de insulina con derivados de triazina y su uso para tratar la diabetes
JP5485292B2 (ja) * 2008-12-12 2014-05-07 ポクセル・エスアーエス Ａｍｐｋ活性に関連する疾患を処置するためのテトラヒドロトリアジン化合物
WO2010103040A1 (en) 2009-03-10 2010-09-16 INSERM (Institut National de la Santé et de la Recherche Médicale) 5'-adenosine monophosphate-activated protein kinase (ampk) activators for treating pulmonary hypertension
US8742102B2 (en) 2009-03-26 2014-06-03 Poxel Process for enantiomeric separation of racemic dihydro-1,3,5 triazines via preferential crystallization
FR2948028B1 (fr) 2009-07-17 2011-12-02 Merck Sante Sas Association d'un inhibiteur de l'echangeur sodium-proton et d'un derive amine de dihydro-1,3,5-triazine
FR2948027A1 (fr) * 2009-07-17 2011-01-21 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion
FR2948026B1 (fr) 2009-07-17 2011-12-02 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine
WO2011154496A1 (en) 2010-06-09 2011-12-15 Poxel Treatment of type 1 diabetes
TWI436768B (zh) 2010-06-09 2014-05-11 Poxel 第２型糖尿病之治療
EP2646422B1 (en) 2010-12-01 2015-07-08 Poxel Separation of triazine derivatives enantiomers using tartaric acid
RU2658819C2 (ru) * 2016-05-26 2018-06-25 федеральное государственное бюджетное образовательное учреждение высшего образования "Самарский государственный технический университет" Применение гетероциклических гидразонов в качестве средств, обладающих антигликирующей активностью
FR3068601B1 (fr) * 2017-07-05 2021-02-19 Eric Joseph Marie Fulgence Janin Utilisation de l'imeglimine pour la prevention et/ou le traitement du carcinome hepatocellulaire
EP3691650A1 (en) 2017-10-02 2020-08-12 Poxel Methods of treating heart failure with preserved ejection fraction
MY203360A (en) * 2018-06-06 2024-06-26 Metavant Sciences Gmbh Methods of treating subjects having diabetes with chronic kidney disease
CA3103324A1 (en) 2018-06-14 2019-12-19 Poxel Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes
WO2022152138A1 (zh) * 2021-01-15 2022-07-21 中国医药研究开发中心有限公司 稠和杂环类化合物及其制备方法和医药用途
CN118955413A (zh) * 2024-07-25 2024-11-15 宁夏恒康科技有限公司 一种盐酸伊美格列明的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3287366A (en) * 1963-12-24 1966-11-22 American Cyanamid Co Novel 1, 2-dihydro-s-triazines
US3286366A (en) * 1964-10-26 1966-11-22 Seligman Monroe Apparatus for freeze drying products in small containers
JPS4856692A (cs) * 1971-11-19 1973-08-09
JPS4864088A (cs) * 1971-12-13 1973-09-05
JPS5414986A (en) * 1977-07-01 1979-02-03 Taiho Pharmaceutical Co Ltd Production of dihydrooss triazine derivative
US4246408A (en) * 1979-03-08 1981-01-20 Icn Pharmaceuticals Imidazo[1,2-a]-s-triazine
GR74944B (cs) * 1980-07-02 1984-07-12 Merck & Co Inc
US4277602A (en) * 1980-07-02 1981-07-07 Merck & Co., Inc. 3-Amino-5-substituted-6-halo-N-(3,4-dihydro-6-substituted-1,3,5-truazin-2-yl)2-pyrazinecarboxamides
US4576945A (en) * 1982-10-26 1986-03-18 Sanders Mark E Hexaalkylmelamine-amino-oxy compounds
JPS6141915A (ja) 1984-08-03 1986-02-28 Omron Tateisi Electronics Co 測距装置
DD257010A1 (de) * 1987-01-13 1988-06-01 Berlin Chemie Veb Ergotrope mittel
DE3801113A1 (de) * 1987-07-23 1989-02-02 Bayer Ag Substituierte triazine
IT1244870B (it) * 1990-09-11 1994-09-12 Ministero Dall Uni E Della Ric Composti ammelinici
DE19641692A1 (de) * 1996-10-10 1998-04-23 Bayer Ag Substituierte 2,4-Diamino-1,3,5-triazine
CN1290264A (zh) * 1997-12-12 2001-04-04 艾博特公司 三嗪类血管生成抑制剂
FR2804113B1 (fr) * 2000-01-26 2004-06-18 Lipha Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique

Also Published As

Publication number Publication date
EP1250328B1 (fr) 2006-07-05
AU782307B2 (en) 2005-07-21
CA2397636C (fr) 2010-04-06
JP4926357B2 (ja) 2012-05-09
HUP0204087A2 (hu) 2003-04-28
HRP20020625A2 (en) 2003-10-31
PL357191A1 (en) 2004-07-26
NO20023532D0 (no) 2002-07-24
FR2804113B1 (fr) 2004-06-18
HU230790B1 (en) 2018-05-02
EP1250328A1 (fr) 2002-10-23
CZ303445B6 (cs) 2012-09-19
WO2001055122A1 (fr) 2001-08-02
OA12165A (fr) 2006-05-08
SI1250328T1 (sl) 2006-10-31
NO20023532L (no) 2002-09-25
CZ20022462A3 (cs) 2003-04-16
BR0107815A (pt) 2002-10-29
HK1050529A1 (en) 2003-06-27
CN1404472A (zh) 2003-03-19
US20080108591A1 (en) 2008-05-08
SI1250328T2 (sl) 2010-09-30
SK9762002A3 (en) 2003-05-02
US20050165022A1 (en) 2005-07-28
IS6467A (is) 2002-07-11
US7034021B2 (en) 2006-04-25
DE60121294T2 (de) 2007-08-30
YU55602A (sh) 2005-03-15
KR100722438B1 (ko) 2007-05-29
AU3560301A (en) 2001-08-07
ZA200205314B (en) 2005-07-27
MA25650A1 (fr) 2002-12-31
DE60121294D1 (de) 2006-08-17
IL150530A0 (en) 2003-02-12
US7767676B2 (en) 2010-08-03
AP2002002578A0 (en) 2002-09-30
EP1250328B2 (fr) 2010-04-21
AR027293A1 (es) 2003-03-19
MXPA02007232A (es) 2003-10-15
US20080108619A1 (en) 2008-05-08
PT1250328E (pt) 2006-10-31
TNSN01012A1 (fr) 2005-11-10
EE200200414A (et) 2003-10-15
US7452883B2 (en) 2008-11-18
CA2397636A1 (fr) 2001-08-02
FR2804113A1 (fr) 2001-07-27
CN1195743C (zh) 2005-04-06
CY1105344T1 (el) 2010-03-03
SK287647B6 (sk) 2011-05-06
DK1250328T4 (da) 2010-06-28
EA005378B1 (ru) 2005-02-24
KR20020075395A (ko) 2002-10-04
EA200200790A1 (ru) 2003-02-27
US20030109530A1 (en) 2003-06-12
DE60121294T3 (de) 2010-09-23
ES2267715T5 (es) 2010-06-10
BRPI0107815B8 (pt) 2021-05-25
BG106933A (en) 2003-07-31
JP2003520858A (ja) 2003-07-08
ATE332294T1 (de) 2006-07-15
BRPI0107815B1 (pt) 2017-08-29
HUP0204087A3 (en) 2006-01-30
ES2267715T3 (es) 2007-03-16
PL205345B1 (pl) 2010-04-30
DK1250328T3 (da) 2006-10-30

Similar Documents

Publication Publication Date Title
EE200200414A (et) Dihüdro-1,3,5-triasiinamino derivaadid ja nende kasutamine ravis
EE04566B1 (et) Epotilooni derivaadid ja nende kasutamine meditsiinis
EE200200251A (et) Uued N-asabitsükloamiidi derivaadid ja nende kasutamine
EE200300048A (et) Bensimidasooli derivaadid, nende valmistamine ja terapeutiline kasutamine
NO20021379D0 (no) Benzodiazepin-derivater, fremstilling og anvendelse derav
DK1354888T3 (da) Glukopyranosyloxypyrazolderivater og anvendelse deraf i medikamenter
FI955235L (fi) Oksatsolidiinionijohdannaiset, niiden valmistus ja käyttö
EE200000723A (et) Asendatud indolinoonid, nende valmistamine ja nende kasutamine ravimitena
EE200100568A (et) 6-alkenüül-, 6-alkünüül- ja 6-epoksüepotilooni derivaadid, nende valmistamismeetod ja kasutamine farmatseutilistes preparaatides
EE200300145A (et) Asa- ja polüasanaftalenüülkarboksamiidid ja farmatseutiline kompositsioon
EE04497B1 (et) Püridopüranoasepiini derivaadid, nende valmistamine ja terapeutiline kasutamine
EE9800459A (et) Spiro-piperidiini derivaadid ja nende kasutamine terapeutiliste toimeainetena
EE05000B1 (et) 2'-asendatud 1,1'-bifenüül-2-karboksamiidid, nende kasutamine ja farmatseutilised preparaadid
FI944600A0 (fi) Imidatsol-4-yylipiperidiinijohdannaisia, niiden valmistus ja niiden käyttö terapiassa
EE200300193A (et) Asendatud bensimidasoolid, nende kasutamine ja ravim
FI956298A7 (fi) 3-fenyyli-isokinolin-1(2H)-oneja, niiden valmistus ja terapeuttinen käyttö
EE9700288A (et) Asatsükloalkaani derivaadid, nende valmistamine ja kasutamine ravis
EE200000056A (et) 4-okso-3,5-dihüdro-4H-püridasino[4.5-b]indool-1-etaanamiidi derivaadid, nende valmistamine ja kasutamine raviks
FI941068A7 (fi) Bentsoksatsiinijohdannaiset, niiden valmistus ja terapeuttinen käyttö
EE9900218A (et) 1,4-diasabitsüklo[2.2.2]okt-2-üülmetüülbensoaadi derivaadid, nende valmistamine ja kasutamine raviks
NO20001934D0 (no) 3-Substituerte tetrahydropyridopyrimidinon-derivater, deres fremstilling og anvendelse
EE9800333A (et) Uued furaandiarüülmetülideeni derivaadid, nende valmistamise meetod ja kasutamine teraapias
EE9900135A (et) N-(2-bensotiasolüül)-1-piperidiinetaanamiini derivaadid, nende valmistamine ja kasutamine raviks
EE200000018A (et) 6-pürrolidiin-2-üülpüridiinid, nende valmistamine ja terapeutiline kasutamine
FI954141L (fi) Oksatsolokinolonijohdannaiset, niiden valmistus ja niiden käyttö terapiassa

Legal Events

Date Code Title Description
HD1A Correction of address
HC1A Change of owner name
KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231